Nintedanib in Idiopathic Pulmonary Fibrosis: Tolerability and Safety in a Real Life Experience in a Single Centre in Patients also Treated with Oral Anticoagulant Therapy
Idiopathic pulmonary fibrosis (IPF) is a rare and severe disease with a median survival of ~3 years. Nintedanib (NTD) has been shown to be useful in controlling interstitial lung disease (ILD) in IPF. Here we describe the experience of NTD use in IPF in a real-life setting. Objective. Our objective...
Spremljeno u:
Glavni autori: | , , , , , , , , , , , , |
---|---|
Format: | Knjiga |
Izdano: |
MDPI AG,
2023-02-01T00:00:00Z.
|
Teme: | |
Online pristup: | Connect to this object online. |
Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|
Internet
Connect to this object online.3rd Floor Main Library
Signatura: |
A1234.567 |
---|---|
Primjerak 1 | Dostupno |